2-(羟甲基)高吗啉盐酸盐 | 1207194-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂卓类
• 中文名称: 2-(羟甲基)高吗啉盐酸盐
• 英文名称: (1,4-oxazepan-2-yl)methanol hydrochloride
• 英文别名: 2-(Hydroxymethyl)homomorpholine Hydrochloride；1,4-oxazepan-2-ylmethanol;hydrochloride
• CAS: 1207194-51-1
• 化学式: C₆H₁₃NO₂*ClH
• 分子量: 167.636
• InChiKey: TYCNWXGJJIVMOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.22
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(tert-butyl) 2-methyl 1,4-oxazepane-2,4-dicarboxylate 在 lithium aluminium tetrahydride 、 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 以99 %的产率得到2-(羟甲基)高吗啉盐酸盐
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

  公开号：

  WO2023018809A1

文献信息

• Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
  申请人：Nurix Therapeutics, Inc.

  公开号：US11530229B2

  公开（公告）日：2022-12-20

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

  本发明公开了用于抑制泛素蛋白酶体途径中的 E3 酶 Cbl-b 的化合物、组合物和方法。这些化合物、组合物和方法可用于调节免疫系统，治疗免疫系统可调节的疾病，以及体内、体外或体外细胞的治疗。还公开了包含 Cbl-b 抑制剂和癌症疫苗的药物组合物，以及使用 Cbl-b 抑制剂和癌症疫苗治疗癌症的方法；以及包含 Cbl-b 抑制剂和溶瘤病毒的药物组合物，以及使用 Cbl-b 抑制剂和溶瘤病毒治疗癌症的方法。
• CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
  申请人：Nurix Therapeutics, Inc.

  公开号：US20210053986A1

  公开（公告）日：2021-02-25

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
• [EN] CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF<br/>[FR] COMPOSÉS CYANO-CYCLOBUTYLE POUR L'INHIBITION DE CBL-B ET LEURS UTILISATIONS
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2020236654A1

  公开（公告）日：2020-11-26

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：[en]AMGEN INC.

  公开号：WO2023018809A1

  公开（公告）日：2023-02-16

  The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.